首页> 外文期刊>International Journal of Chronic Obstructive Pulmonary Disease >VitalQPlus: a potential screening tool for early diagnosis of COPD
【24h】

VitalQPlus: a potential screening tool for early diagnosis of COPD

机译:VitalQPlus:早期诊断COPD的潜在筛选工具

获取原文
       

摘要

Background: This study utilized a validated combination of a COPD Population Screener (COPD-PS) questionnaire and a handheld spirometric device as a screening tool for patients at high risk of COPD, such as smokers. The study aimed to investigate and pilot the feasibility and application of this combined assessment, which we termed the “VitalQPlus”, as a screening tool for the early detection of COPD, especially in primary care settings. Methods: This was a cross-sectional study screening potentially undiagnosed COPD patients using a validated five-item COPD-PS questionnaire together with a handheld spirometric device. Patients were recruited from selected Malaysian government primary care health centers. Results: Of the total of 83 final participants, only 24.1% (20/83) were recruited from Perak and Penang (peninsular Malaysia) compared to 75.9% (63/83) from Sabah (Borneo region). Our dual assessment approach identified 8.4% of the surveyed patients as having potentially undiagnosed COPD. When only the Vitalograph COPD-6 screening tool was used, 15.8% of patients were detected with a forced expiratory volume in 1 second/forced expiratory volume in 6 seconds (FEV1/FEV6) ratio at <0.75, while 35.9% of patients were detected with the COPD-PS questionnaire. These findings suggested that this dual assessment approach has a greater chance of identifying potentially undiagnosed COPD patients compared to the Vitalograph COPD-6 or COPD-PS questionnaire when used alone. Our findings show that patients with more symptoms (scores of ≥5) yielded twice the percentage of outcomes of FEV1/FEV6 <0.75 compared to patients with fewer COPD symptoms (scores <5). Conclusion: With the availability of a simple screening questionnaire and the COPD-6, there is an opportunity easily to make patients more aware of their lung symptoms and to encourage the provision of early treatment. The proposed dual assessment approach, which we termed the VitalQPlus, may play a profound role in the early diagnosis of COPD, which is crucial in improving the clinical management of the disease.
机译:背景:这项研究利用了COPD人口筛查仪(COPD-PS)问卷和手持式肺活量测定仪的有效组合,作为针对COPD高危患者(如吸烟者)的筛查工具。这项研究旨在调查和试行这种联合评估的可行性和应用,我们将其称为“ VitalQPlus”,作为早期检测COPD的筛查工具,尤其是在初级保健机构中。方法:这是一项横断面研究,使用经过验证的五项COPD-PS问卷和手持式肺活量测定仪对未诊断出的COPD患者进行筛查。患者是从选定的马来西亚政府初级保健健康中心招募的。结果:在总共83名最终参与者中,只有24.1%(20/83)是从霹雳州和槟城(马来西亚半岛)招募的,而沙巴(婆罗洲地区)是75.9%(63/83)。我们的双重评估方法确定了8.4%的被调查患者具有潜在的未被诊断的COPD。仅使用Vitalograph COPD-6筛查工具时,检出15.8%的患者,1秒内的呼气量/ 6秒内的呼气量(FEV1 / FEV6)的比率小于0.75,而检出的患者为35.9%用COPD-PS问卷。这些发现表明,与单独使用Vitalograph COPD-6或COPD-PS调查表相比,这种双重评估方法有更大的机会识别可能未被诊断的COPD患者。我们的发现表明,症状较轻(得分≥5)的患者产生的FEV1 / FEV6 <0.75结局百分率是COPD症状较少(得分<5)的患者的两倍。结论:有了简单的筛查问卷和COPD-6,就有机会轻松地使患者更加了解自己的肺部症状并鼓励提供早期治疗。所提出的双重评估方法(我们称为VitalQPlus)可能在COPD的早期诊断中发挥重要作用,这对改善疾病的临床管理至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号